Benzinga | Jun 8, 2021 08:12AM EDT

Outlook Therapeutics Reports Completion Of Patient Dosing In The ONS-5010 Pivotal Phase 3 NORSE TWO Trial

* Topline readout of data from NORSE TWO targeted for calendar Q3 2021

* New Biologics License Application (BLA) filing anticipated in calendar Q1 2022

ISELIN, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, reported today that it has administered the final dose to the last patient enrolled in its pivotal NORSE TWO safety and efficacy study evaluating ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (wet AMD). Topline data are expected to be reported for NORSE TWO in the third calendar quarter of 2021.